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Abstract 
A hepta-guanidino-β-cyclodextrin (G-CD), its hepta-PEG conjugate (G-CD-PEG), and 
the corresponding anisamide-terminated PEG conjugate (G-CD-PEG-AA) have been 
synthesised and compared as delivery vectors for siRNA to prostate cancer cells and 
tumours in vivo. The G-CD-PEG-AA.siRNA formulations (in which anisamide targets 
the sigma receptor), but not the non-targeted formulations, induced prostate 
cell-specific internalisation of siRNA resulting in approximately 80% knockdown in 
vitro of the reporter gene, luciferase. Following intravenous administration of the 
anisamide-targeted formulation in a mouse prostate tumour model significant tumour 
inactivation with corresponding reductions in the level of vascular endothelial growth 
factor (VEGF) mRNA were achieved, without demonstrating enhanced toxicity. This 
data imply significant potential for anisamide-conjugated cyclodextrin vectors for 
targeted delivery of therapeutic siRNAs in the treatment of prostate cancer. 
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1. Introduction 
As a leading cause of cancer-related deaths (over 32,000 fatalities annually in the male 
population of the United States [1]), prostate cancer is an obvious disease state 
demanding safe and effective treatment. The expanding knowledge of the genetic basis 
of cancer has recently promoted the application of RNA interference (RNAi) as a new 
generation of cancer therapeutics [2,3]. However, the clinical potential of siRNA is 
greatly retarded by inept delivery [4-7].  
We have developed a strategy which uses cyclodextrins (CDs) as core molecules for 
gene delivery [8-13]. There are particular advantages associated with this approach: 
cyclodextrins have low immunogenicity and are unique among oligosaccharides in 
providing chemically equivalent multiple sites for attachment of functional groups 
such as ions, lipophiles, polyethylene glycol and targeting ligands [14-17]. 
The sigma receptor, a membrane bound protein, is known to be overexpressed on many 
human malignancies including prostate cancer [18]. This receptor binds haloperidol 
and various other neuroleptics showing a high affinity with the anisamide moiety. 
Anisamide-conjugated nanoparticles have achieved site-specific delivery of siRNAs in 
certain cancers [19-21]. The aim of this study was to synthesise an anisamide-targeted 
pegylated cyclodextrin and to evaluate this as a delivery vector for siRNA in prostate 
tumours. To achieve this, a hepta-guanidino-β-cyclodextrin (G-CD) was grafted to 
polyethylene glycol chains (giving G-CD-PEG), which acted as a spacer for the 
attachement of the anisamide-targeting moiety (in G-CD-PEG-AA). The presence of 
the cationic guanidino group enables binding and charge neutralization of the siRNA 
and the presence of the PEG is designed to stabilise the nanoparticles in physiological 
environments thereby prolonging their systemic circulation.  
In most tumours new blood vessels are formed via a process termed angiogenesis, from 
pre-existing vasculature [3]. Consequently, VEGF (one of the most important 
angiogenesis oncogenes) has been investigated as an anti-angiogenesis target [22-25]. 
Accordingly, complexes of the anisamide-targeted cyclodextrin with anti-VEGF siRNA 
 4 
were investigated here for their efficacy in a mouse prostate carcinoma model. 
 
2. Materials and methods 
2.1 Synthesis of the modified cyclodextrins 
Monomethyl-PEG500 and 1-amino-3,6,9,12,15,18,21,24,27,30-decaoxadotriacontyl 
32-azide were obtained from Aldrich. To simplify nomenclature, 
3,6,9,12,15,18,21,24,27,30-decaoxadotriacontyl is referred to as 1-deoxy-PEG440-yl. 
tert-Butyl-N-(2-mercaptoethyl) carbamate [26] and anisic acid N-hydroxysuccinimide  
[27] were synthesised by literature methods. Heptakis(6-bromo)-β-cyclodextrin and 
heptakis(6-O-tert-butyldimethylsilyl)-β-cyclodextrin [28,29] were synthesised by 
literature methods.  
Heptakis(6-O-tert-butyldimethylsilyl-2-O-propargyl)-β-cyclodextrin (7) and 
heptakis(6-bromo-6-deoxy-2-O-propargyl)-β-cyclodextrin (8) were synthesised as 
previously described by us [13]. 
Three new CD-based compounds were synthesised as described below. In compound 5 
the CD was modified on the primary face with guanidino to give a cationic cyclodextrin 
(G-CD) (Figure1a). A separate synthetic process, as outlined in Figure 1b, resulted in the 
production of two further CDs. Both of these CDs retain the cationic guanidino on the 
primary side but are further modified on the secondary side initially with a PEG chain 
resulting in a PEGylated cationic CD (G-CD-PEG) (11a). This PEG chain was then used 
as a linker for attachement of the targeting ligand anisamide to produce the third 
compound (G-CD-PEG-AA) (11b) (Figure 1b). 
2.1.1 Heptakis(6-Boc-aminoethylthio)-β-cyclodextrin (2) 
tert-Butyl-N-(2-mercaptoethyl)carbamate (2.8313 g, 16 mmol, 19.5 eq.) was dissolved 
in 50 ml of anhydrous DMF. Sodium hydride (38 mg, 16 mmol, 19.5 eq.) was added 
and the mixture was stirred at 60 °C for 2 hours under nitrogen. 
Heptakis(6-bromo)-β-cyclodextrin (1.3 g, 0.8 mmol, 1 eq.) (dried under vacuum 
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overnight) was added to the solution and the mixture stirred at 60 °C overnight. The 
solvent was evaporated and product precipitated in cyclohexane. The precipitate was 
washed several times with water and cyclohexane to give product (2) in quantitative 
yield. 
1
H NMR (400 MHz, DMSO-d6) δ 6.65-6.85 (m, 1H), 5.65-6.05 (m, 3H), 4.75-4.90 (m, 
1H), 3.65-4.1 (m, 2H), 3.50-3.65 (m, 1H), 3.20-3.50 (m, 3H), 3.00-3.15 (m, 2H), 
2.50-2.70 (m, 2H), 1.25-1.45 (m, 9H).  
13
C NMR (101 MHz, DMSO-d6) δ 155.93, 102.71, 78.15, 72.85, 40.45, 39.89, 38.10, 
34.44, 33.00, 30.50, 28.66.  
2.1.2 Heptakis(6-Boc-aminoethylthio-2-O-propargyl)-β-cyclodextrin (3) 
Heptakis(6-Boc-aminoethylthio)-β-cyclodextrin (2) (309 mg, 0.14 mmol, 1 eq),  
dissolved in 40 ml of anhydrous DMF, was cooled to 0 °C before addition of 33 mg 
(1.37 mmol, 10 eq) of sodium hydride (95% in oil). After stirring for 12 hours at 0 °C, 
then at room temperature (RT), the solution was cooled to 0 °C and 150 µl (1.37 mmol, 
10 eq) of propargyl bromide (80% in toluene) was added before stirring at RT for 12 
hours. The solution was concentrated under reduced pressure and the residue purified 
by column chromatography over SiO2 (ethyl acetate-cyclohexane 1:1) to give product 
(3) (66 mg, 20%). 
1H NMR (400 MHz, CDCl3) δ 5.32 (m, 1H), 5.01 (m, 1H), 4.80 (m, 1H), 4.55 (m, 
2H), 3.90 (m, 2H), 3.66 (m, 2H), 3.48 (m, 1H), 3.32 (m, 2H), 3.09 (m, 1H), 2.75 (m, 
2H), 2.51 (m, 1H), 1.44 (m, 9H).  
13
C NMR (101 MHz, CDCl3) δ 155.88, 101.43, 85.77, 79.19, 78.56, 75.07, 73.18, 
70.84, 59.51, 40.03, 33.42, 31.61, 29.62, 28.49. MALDI-MS: 2507.11 [M+H]
+
, 
2529.53 [M+Na]
+
. 
2.1.3 Heptakis(6-aminoethylthio-2-O-propargyl-)-β-cyclodextrin trifluoroacetate (4) 
Heptakis(6-Boc-aminoethylthio-2-O-propargyl)-β-cyclodextrin (3) (66 mg) was 
dissolved in 50 ml of dichloromethane and 500 µl of trifluoroacetic acid was added. 
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The solution was stirred at 0 °C for 5 hours. The solution was concentrated under 
reduced pressure and purified by size exclusion chromatography over SEPHADEX 
LH20 (methanol, 100) (Rf = 0.05 CH2Cl2/MeOH 8/2) to give product (4) in 
quantitative yield. MALDI-MS: 1817.06 [M+H]
+
, 1839.31 [M+Na]
+
. 
2.1.4 Heptakis(6-guanidinoethylthio-2-O-propargyl-)-β-cyclodextrin trifluoroacetate 
(5)  
2-Propargyl-6-thioethylamine-CD (55 mg, 0.02 mmol, 1 eq) was dissolved in 5mL of 
dichloromethane. 1,3-Di-Boc-2-(trifluoromethylsulfonyl)guanidine (52 mg, 0.133 
mmol, 6.3 eq) (Aldrich) was added with 24 µl of triethylamine. 
The solution was stirred under N2 at room temperature for 12 hours. The solution was 
diluted with 10 ml of dichloromethane and extracted twice with potassium bisulfide 
and brine. The solution was concentrated under reduced pressure and purified by 
column chromatography over SiO2 (CH2Cl2/MEOH 95/5 – Rf = 0.40 90/10 
CH2Cl2/MEOH). 
1
H NMR (400 MHz, CDCl3) δ 11.49 (s, 1H), 8.60 (s, 1H), 5.00 (s, 1H), 4.74 (s, 1H), 
4.53 (m, 2H), 3.80-4.01 (m, 2H), 3.54-3.76 (m, 4H), 2.72-3.07 (m, 2H), 2.51 (s, 1H), 
1.44-1.57 (m, 18H). 
13
C NMR (101 MHz, CDCl3) δ 163.58, 156.03, 153.01, 101.43, 
82.98, 79.23, 79.07, 75.51, 73.18, 71.16, 59.47, 53.42, 33.09, 29.70, 27.86.  
The previous product was dissolved in 5 ml of dichloromethane and 500 µl of TFA. 
The solution was stirred at 0 °C for 5 hours. The solution was concentrated under 
reduced pressure and purified by size exclusion chromatography over SEPHADEX 
LH20 (methanol, 100) to yield 19.1 mg of 2-propargyl-6-thioethylguanidine-CD (5). 
1
H NMR (400 MHz, CD3OD) δ 7.42 (s, 2H), 5.02 (m,1H), 4.53 (m, 2H), 4.16 (m, 2H), 
3.78-3.98 (m, 2H), 3.61-3.71 (m, 1H), 3.50-3.59 (m, 1H), 3.38-3.46 (m, 1H), 3.00-3.14 
(m, 1H), 2.71-2.96 (m, 2H), 2.59-2.68 (m,1H). MALDI-MS: 2109 [M+H]
+
.  
2.1.5 -Methoxy-O-methylsulfonyl-PEG500 
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Monomethyl-PEG500 1.42 g (2.57 mmol, 1 eq.) was dissolved in 80 ml of DCM and 3.2 
ml (18.02 mmol, 7 eq.) of di-isopropylethylamine. The solution was cooled to 0 °C and 1 
ml (12.87 mmol, 5 eq.) of methylsulfonyl chloride was added. The solution was stirred 
for 12 hours at RT under nitrogen, then concentrated under reduced pressure and the 
residue purified by column chromatography over SiO2 (CH2Cl2/methanol, 95:5) to give 
product (1.52 g, 94%). 
1
H NMR (500 MHz, cdcl3) δ 4.27 – 4.22 (m, 2H), 3.66 – 3.62 (m, 2H), 3.62 – 3.45 (m, 
40H), 3.43 – 3.40 (m, 2H), 3.24 (s, 3H), 2.96 (s, 3H). 13C NMR (126 MHz, cdcl3) δ 
71.70, 70.53 – 69.85 (m), 69.19, 68.77, 58.72, 37.45. MS (ESI-/TOF) m/z: 506.73 (16%) 
[M-H]
-
 ; 551.16 (57%) [M-H]
-
 ; 595.28 (73%) [M-H]
-
 ; 639.13 (81%) [M-H]
-
 ; 683.30 
(100%) [M-H]
-
 ; 727.29 (96%) [M-H]
-
 ; 771.21 (65%) [M-H]
-
 ; 859.40 (23%) [M-H]
-
 ; 
903.41 (12%) [M-H]
-
. 
2.1.6 - Methoxy-PEG500-yl azide 
-Methoxy-O-methylsulfonyl-PEG500 (1.52 g, 2.38 mmol, 1 eq.) was dissolved in 30 ml 
of DMF. 620 mg (9.55 mmol, 4 eq.) of sodium azide was added. The solution was heated 
at 80 °C overnight. The solution was concentrated under reduced pressure and the 
residue was purified by column chromatography over SiO2 (CH2Cl2/methanol, 95:5) to 
give product (1.21 g, 87%). 
1
H NMR (400 MHz, cdcl3) δ 3.70 – 3.50 (m, 48H), 3.50 – 3.44 (m, 2H), 3.34 – 3.28 (m, 
5H). 
13
C NMR (101 MHz, cdcl3) δ 71.85, 70.91 – 70.18 (m), 69.95, 58.93, 50.60. MS 
(ESI
+
/TOF) m/z: 476.15 (15%) [M+Na]
+
 ; 520.14 (51%) [M+Na]
+
 ; 564.14 (100%) 
[M+Na]
+
 ; 608.19 (93%) [M+Na]
+
 ; 652.18 (62%) [M+Na]
+
 ; 696.24 (26%) [M+Na]
+
 ; 
740.29 (15%) [M+Na]
+
. 
2.1.7 Heptakis[6-bromo-6-deoxy-2-O-(N-(-methoxy--PEG500-yl)-1'H-triazole-4'-yl-
methyl)]--cyclodextrin (9a) 
Heptakis(6-bromo-6-deoxy-2-O-propargyl)-β-cyclodextrin (8) (100 mg, 0.054 mmol, 1 
eq.) and 317 mg (0.54 mmol, 10 eq.) of-methoxy-O-methoxy-PEG500 -yl- azide were 
dissolved in 6 ml of DMF and 6 ml of water. Copper (II) sulphate pentahydrate (13.5 
 8 
mg, 0.054 mmol, 1 eq.) was added, then 32 mg (0.16 mmol, 3 eq.) of sodium ascorbate, 
and the solution was stirred at 80 °C for 12 hours. The solution was concentrated under 
reduced pressure and the residue purified by size exclusion chromatography over 
Sephadex LH20 (methanol 100%) to give product (9a) (282 mg, 88%). 
1
H NMR (400 MHz, cdcl3) δ 7.90 (s, 1H), 5.07 – 4.89 (m, 3H), 4.84 (s, 1H), 4.69 – 
4.47 (m, 1H), 4.01 – 3.23 (m, 52H). 13C NMR (101 MHz, cdcl3) δ 143.62, 124.66, 
101.35, 85.54, 78.41, 73.15 – 69.03 (m, 23), 64.90, 58.97, 50.25, 33.01. 
2.1.8 Heptakis[6-Boc-aminoethylthio-2-O-(N-(-methoxy--PEG500-yl)-1'H-triazole-
4'-yl-methyl)]--cyclodextrin  
tert-Butyl-N-(2-mercaptoethyl)carbamate (242 mg, 1.36 mmol, 28 eq.) and 33 mg 
(1.36 mmol, 28 eq.) of sodium hydride were dissolved in 25 ml of anhydrous DMF. 
The solution was stirred at 80 °C under nitrogen for 2 hours. The solution was then 
cooled to room temperature and 282 mg (0.05 mmol, 1 eq.) of 8a in 5 ml of anhydrous 
DMF was added. The solution was stirred overnight at 80 °C under nitrogen, then 
concentrated under reduced pressure and the residue purified by size exclusion column 
chromatography over Sephadex LH20 (methanol 100%) to give product (285 mg, 
90%). 
1
H NMR (500 MHz, cdcl3) δ 7.87 (s, 1H), 5.54 – 5.25 (m, 1H), 5.08 – 4.84 (m, 3H), 4.83 
– 4.74 (m, 1H), 4.64 – 4.53 (m, 2H), 3.97 – 3.90 (m, 2H), 3.90 – 3.44 (m, 46H), 3.38 (s, 
3H), 3.32 – 3.22 (m, 2H), 3.13-2.95 (m, 1H), 2.76 – 2.61 (m, 2H), 1.42 (s, 9H). 13C NMR 
(126 MHz, cdcl3) δ 155.87, 143.93, 124.49, 101.34, 85.70, 79.14, 73.02, 71.95, 70.58, 
69.49, 65.21, 59.00, 50.20, 40.08, 33.43, 28.54. 
2.1.9 Heptakis[6-aminoethylthio-2-O-(N-(-methoxy--PEG500-yl)-1'H-triazole-4'-yl-
methyl)]--cyclodextrin trifluoroacetate (10a) 
Heptakis[6-(Boc-aminoethylthio)-2-O-(N-(-methoxy--PEG500-yl)-1'H-triazole-4'-yl-
methyl)]--cyclodextrin (285 mg, 0.044 mmol) was dissolved in 50 ml of DCM and 20 
ml of trifluoroacetic acid. The solution was stirred for 6 hours at RT. The solution was 
concentrated under reduced pressure and purified by purified by size exclusion column 
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chromatography over Sephadex LH20 (methanol 100%) to give product (10a) (250 
mg, 86%). 
1
H NMR (400 MHz, cdcl3) δ 8.72 – 7.91 (m, 3H), 7.91 – 7.38 (m, 1H), 5.19 – 4.25 (m, 
6H), 3.96 – 2.59 (m, 54H). 13C NMR (101 MHz, cdcl3) δ 162.48 – 160.35 (m), 143.85, 
124.60, 119.78 – 113.18 (m), 101.12, 84.97, 78.62, 73.01, 71.84, 70.98 – 69.86 (m, 
23C), 69.35, 64.94, 58.95, 50.19, 38.58, 30.11. MALDI–MS: Mavg=5808.45 g/mol. 
2.1.10 Heptakis[6-diBoc-guanidinoethylthio-2-O-(N-(-methoxy--PEG500-yl)-1'H-tria
zole-4'-yl-methyl)]--cyclodextrin 
Heptakis[6-(2''-aminoethylthio)-2-O-(N-(-methoxy--PEG500-yl)-1'H-triazole-4'-yl-me
thyl)]--cyclodextrin trifluoroacetate (250 mg, 0.038 mmol, 1eq.) was dissolved in 50 
ml of DCM and 1 ml of di-isopropylethylamine. 
N,N′-diBoc-1H-pyrazole-1-carboxamidine (580 mg, 1.87 mmol, 50 eq.) (Aldrich) was 
added. The solution was stirred at RT under N2 for 12 hours. The solution was 
concentrated under reduced pressure and the residue was purified by size exclusion 
chromatography over Sephadex LH20 (methanol, 100) to give product (208 mg, 73%). 
1
H NMR (400 MHz, cdcl3) δ 11.40 (s, 1H), 8.75 – 8.22 (m, 1H), 7.76 (s, 1H), 5.09 – 4.62 
(m, 4H), 4.56 – 4.42 (m, 2H), 3.97 – 3.68 (m, 4H), 3.63 – 3.33 (m, 46H), 3.29 (s, 3H), 
3.04 – 2.40 (m, 4H), 1.65 – 1.08 (m, 18H). 13C NMR (101 MHz, cdcl3) δ 163.59, 156.04, 
152.98, 144.00, 124.36, 101.35, 85.28, 82.92, 79.40, 78.98, 73.11, 71.97, 71.29, 70.88 – 
70.11 (m, 22C), 69.53, 65.47, 59.06, 50.58, 50.18, 39.86, 32.93, 28.40, 28.14. 
2.1.11 Heptakis[6-guanidinoethylthio-2-O-(N-(-methoxy--PEG500-yl)-1'H-triazole-4'
-yl-methyl)]--cyclodextrin trifluoroacetate (11a) 
Heptakis[6-(diBoc-guanidinoethylthio)-2-O-(N-(-methoxy--PEG500-yl)-1'H-triazole-
4'-yl-methyl)]--cyclodextrin (208 mg) was dissolved in 10 ml of DCM and 10 ml of 
trifluoroacetic acid. The solution was stirred for 6 hours at RT. The solution was 
concentrated under reduced pressure and dried under high vacuum for 12 hours to give 
product (215 mg, quant.). 
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1
H NMR (500 MHz, cdcl3) δ 11.07 – 9.55 (m, 2H), 7.95 (s, 1H), 7.50 (s, 1H), 6.89 (s, 
3H), 5.23 – 4.40 (m, 6H), 3.93 – 3.22 (m, 53H), 2.99 – 2.33 (m, 4H). 13C NMR (126 
MHz, cdcl3) δ 160.45 (q, J = 37.4 Hz), 157.38, 143.48, 125.46, 115.88 (q, J = 289.3 Hz), 
101.19, 85.11, 79.12, 72.99, 71.89, 71.46, 71.25 – 69.83 (m, 22C), 69.20, 64.34, 58.96, 
50.73, 41.01, 32.32. MALDI-MS: Mavg=6086.13 g/mol. 
2.1.12 1-Deoxy--(p-methoxybenzamido)-PEG440-yl azide 
1-Amino-3,6,9,12,15,18,21,24,27,30-decaoxadotriacontyl 32-azide (133 mg, 0.25 
mmol, 1 eq.), 284 mg (1.14 mmol, 4.5 eq.) of anisic acid N-hydroxysuccinimide and 
330 μl (1.90 mmol, 7.6 eq.) of di-isopropylethylamine were dissolved in 25 ml of DCM. 
The solution was stirred in the dark at RT under nitrogen for 12 hours, concentrated 
under reduced pressure and purified by column chromatography over silica 
(CH2Cl2-methanol, 95:5 to 90:10) to give product (167 mg, quant.). 
1
H NMR (600 MHz, cdcl3) δ 7.79 – 7.74 (m, 2H), 6.93 – 6.87 (m, 2H), 6.73 (s, 1H), 3.83 
(s, 3H), 3.70 – 3.55 (m, 42H), 3.37 (t, J = 5.1 Hz, 2H). 13C NMR (151 MHz, cdcl3) δ 
167.15, 129.04, 127.17, 113.84, 71.98 – 69.33 (m), 55.57, 50.91, 39.93. MS (ESI+/TOF) 
m/z: 661.34 (100) [M+H]
+
 ; 683.33 (41) [M+Na]
+
 ; 699.29 (34) [M+K]
+
. 
2.1.13 Heptakis[6-bromo-6-deoxy-2-O-(N-(p-methoxybenzamido)-PEG440-yl)-1'H-
triazole-4'-yl-methyl)]--cyclodextrin (9b) 
Heptakis(6-bromo-6-deoxy-2-O-propargyl)-β-cyclodextrin (54 mg, 0.029 mmol, 1 eq.) 
and 192.9 mg (0.29 mmol, 10 eq.) of 1-deoxy--(p-methoxybenzamido)-PEG440-yl 
azide were dissolved in 5 ml of DMF and 5 ml of water. Copper (II) sulfate 
pentahydrate (7.25 mg, 0.029 mmol, 1 eq.) was added, then 17.2 mg (0.087 mmol, 3 
eq.) of sodium ascorbate was added and the solution was stirred at 80 °C for 12 hours. 
The solution was concentrated under reduced pressure and purified by size exclusion 
column chromatography over Sephadex LH20 (methanol 100%) to give product (9b) 
(153 mg, 82%). 
1
H NMR (400 MHz, cdcl3) δ 7.85 (s, 1H), 7.73 (d, J = 8.3 Hz, 2H), 6.87 (d, J = 8.3 Hz, 
2H), 6.75 (s, 1H), 5.21 – 4.69 (m, 5H), 4.60 – 4.46 (m, 2H), 4.00 – 3.12 (m, 50H). 13C 
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NMR (101 MHz, cdcl3) δ 166.97, 162.04, 143.60, 128.84, 126.85, 124.69, 113.60, 
101.36, 85.56, 78.42, 72.76, 71.20 – 69.65 (m, 18C), 69.34, 64.88, 55.36, 50.30, 39.70, 
33.03. MALDI-MS: 6492.21 [M+H]
+
 ; 6533.64 [M+K]
+
. 
2.1.14 Heptakis[6-Boc-aminoethylthio-2-O-(N-(p-methoxybenzamido)-PEG440-yl)
-1'H-triazole-4'-yl-methyl)]--cyclodextrin 
tert-Butyl-N-(2-mercaptoethyl)carbamate (117 mg, 0.66 mmol, 28 eq.) and 15.8 mg 
(0.66 mmol, 28 eq.) of sodium hydride were dissolved in 25 ml of anhydrous DMF. 
The solution was stirred at 80 °C under nitrogen for 2 hours. The solution was then 
cooled to room temperature and 153 mg (0.024 mmol, 1 eq.) of 
heptakis[6-bromo-6-deoxy-2-O-(N-(p-methoxybenzamido)-PEG440-yl)-1'H-triazol
e-4'-yl-methyl)]--cyclodextrin in 5 ml of anhydrous DMF was added. The solution 
was stirred overnight at 80 °C under nitrogen. The solution was concentrated under 
reduced pressure and purified by purified by size exclusion column chromatography 
over SEPHADEX LH20 (methanol 100%) to give product (146 mg, 86%). 
1
H NMR (500 MHz, cdcl3) δ 7.83 (s, 1H), 7.75 (d, J = 8.7 Hz, 2H), 6.89 (d, J = 8.7 Hz, 
2H), 6.73 (s, 1H), 5.35 (s, 1H), 5.05 – 4.84 (m, 3H), 4.76 (s, 1H), 4.60 – 4.51 (m, 2H), 
3.95 – 3.84 (m, 3H), 3.82 (s, 3H), 3.70 – 3.42 (m, 40H), 3.39 – 2.47 (m, 9H), 1.40 (s, 
9H). 
13
C NMR (126 MHz, cdcl3) δ 167.06, 162.17, 155.99, 144.03, 128.96, 127.03, 
124.61, 113.74, 101.40, 85.80, 79.24 (2C), 73.11, 71.11 – 69.82 (m, 18C), 69.57, 65.27, 
55.50, 50.29, 40.17, 39.83, 33.52 (2C), 28.63. 
2.1.15 Heptakis[6-aminoethylthio-2-O-(N-(p-methoxybenzamido)-PEG440-yl)-1'H
-triazole-4'-yl-methyl)]--cyclodextrin trifluoroacetate (10b) 
Heptakis[6-(Boc-aminoethylthio)-2-O-(N-(p-methoxybenzamido)-PEG440-yl)-1'H-t
riazole-4'-yl-methyl)]--cyclodextrin (146 mg) was dissolved in 10 ml of DCM and 10 
ml of trifluoroacetic acid. The solution was stirred for 6 hours at room temperature. 
The solution was concentrated under reduced pressure and dried under high vacuum 
for 12 hours to give product (10b) (150 mg, quant.). 
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1
H NMR (500 MHz, cdcl3) δ 8.12 (s, 1H), 7.76 (d, J = 8.5 Hz, 2H), 7.64 – 7.17 (m, 4H), 
6.92 (d, J = 8.6 Hz, 2H), 5.25 – 4.74 (m, 3H), 4.62 (s, 2H), 4.08 – 2.54 (m, 56H). 13C 
NMR (126 MHz, cdcl3) δ 169.25, 162.93, 161.08 – 158.21 (m), 142.49, 129.35, 126.47, 
125.49, 118.47 – 114.30 (m, J = 276.0 Hz), 114.07, 101.03, 84.84, 79.15, 73.04, 71.70 – 
68.34 (m, 19C), 63.24, 55.55, 51.47, 40.27, 39.41, 32.52, 30.44. MALDI-MS: 6470.93 
[M+H]
+ 
; 6511.42 [M+K]
+
. 
2.1.16 Heptakis[6-diBoc-guanidinoethylthio-2-O-(N-(p-methoxybenzamido)-PEG
440-yl)-1'H-triazole-4'-yl-methyl)]--cyclodextrin 
Heptakis[6-aminoethylthio-2-O-(N-(p-methoxybenzamido)-PEG440-yl)-1'H-triazol
e-4'-yl-methyl)]--cyclodextrin trifluoroacetate (150 mg, 0.020 mmol, 1eq.) was 
dissolved in 50 ml of DCM and 1 ml of di-isopropylethylamine. 
N,N′-diBoc-1H-pyrazole-1-carboxamidine (311 mg, 1.00 mmol, 50 eq.) was added. The 
solution was stirred at RT under nitrogen for 12 hours. The solution was then 
concentrated under reduced pressure and the residue was purified by size exclusion 
chromatography over Sephadex LH20 (methanol, 100) to give product (133 mg, 81%). 
1
H NMR (500 MHz, cdcl3) δ 11.42 (s, 1H), 8.47 (s, 1H), 7.78 (s, 1H), 7.72 (d, J = 8.8 Hz, 
2H), 6.85 (d, J = 8.8 Hz, 2H), 6.80 – 6.73 (m, 1H), 5.03 – 4.67 (m, 4H), 4.56 – 4.45 (m, 
2H), 3.97 – 3.18 (m, 51H), 3.07 – 2.32 (m, 4H), 1.59 – 1.29 (m, 18H). 13C NMR (126 
MHz, cdcl3) δ 167.04, 163.63, 162.14, 156.09, 153.03, 144.04, 128.95, 127.00, 124.40, 
113.70, 101.39, 85.34, 82.96, 80.05 – 78.59 (m, 2C), 73.14, 71.97 – 68.61 (m, 19C), 
65.50, 55.47, 50.23, 39.80 (s, 2C), 32.97, 29.03 – 27.47 (m, 7C). 
2.1.17 Heptakis[6-guanidinoethylthio-2-O-(N-(p-methoxybenzamido)-PEG440-yl)-
1'H-triazole-4'-yl-methyl)]--cyclodextrin trifluoroacetate (11b) 
Heptakis[6-diBoc-guanidinoethylthio-2-O-(N-(p-methoxybenzamido)-PEG440-yl)-
1'H-triazole-4'-yl-methyl)]--cyclodextrin (100 mg) was dissolved in 10 ml of DCM 
and 10 ml of trifluoroacetic acid. The solution was stirred for 6 hours at room 
temperature, then  concentrated under reduced pressure and the residue dried under 
high vacuum for 12 hours to give product (11b) (105 mg, quant.). 
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1
H NMR (500 MHz, cdcl3) δ 8.19 (s, 1H), 7.78 (d, J=10 Hz, 2H), 7.31 (s, 2H), 6.95 (d, J 
= 10 Hz, 2H), 6.70-6.80 (m, 2H), 5.10 – 4.80 (m, 3H), 4.70 – 4.4.60 (m, 2H), 4.05 – 3.30 
(m, 51H), 3.10 – 2.35 (m, 4H). 
13
C NMR (126 MHz, cdcl3) δ 169.16, 162.76, 160.12-159.18 (1C), 157.05, 141.97, 
129.14, 126.42, 125.19, 118.75, 116.44, 114.14, 113.89, 111.86, 100.63, 84.36, 79.30, 
72.81, 71.16, 70.71-69.58 (19C), 69.27, 68.45, 62.90, 55.35, 51.57, 40.81, 40.15, 32.51, 
32.12. MALDI-MS: 6745.46; 6797.07.  
2.2 Preparation and characterisation of cyclodextrin complexes with siRNA 
The cyclodextrins (G-CD, G-CD-PEG and G-CD-PEG-AA) were dissolved in aqueous 
solutions (deionised water and phosphate buffer saline (PBS)), before addition of 
siRNA solution (prepared in RNase-free water following QIAGEN and SIGMA 
recommendations) at different mass ratios (MRs) of cyclodextrins to siRNA, followed 
by 1-hour incubation at RT. 
The ability of cyclodextrins to complex siRNA was analysed by gel retardation [25]. 
Complexes of cyclodextrins and siRNA (containing 0.5 g siRNA) at different mass 
ratios were prepared as described above and loaded onto 1% (w/v) agarose gels in 
Tris/Borate/EDTA (TBE) buffer containing ethidium bromide. Electrophoresis was 
performed at 120 V for 30 minutes and the resulting gels were photographed under 
UV. 
The morphology of cyclodextrins with siRNA was examined using transmission 
electron microscopy (TEM) [30]. Cyclodextrins or complexes (MR = 75) containing 
0.5 µg siRNA in deionised water (deionised water was filtered through a 0.2 µm 
membrane) were left on 400-mesh carbon-filmed copper grids (Agar Scientific) for 
several minutes, then grids were blotted with filter paper. The grids were then stained 
with 2% (w/w) uranyl acetate, blotted again and left at RT overnight. Samples were 
analysed using a JEOL 2000 FXII transmission electron microscope (Jeol Ltd., Tokyo, 
Japan). 
Particle sizes and zeta potentials were measured with a Malvern Nano-ZS (Malvern 
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Instruments, UK). PBS (0.2 µm membrane-filtered, used for particle size analysis) and 
deionised water (0.2 µm membrane-filtered, applied for zeta potential evaluation) were 
added to the cyclodextrin or the complexes and made up to 1 ml, 4 hours before 
measurement. The concentration of cyclodextrins (cyclodextrins alone and 
cyclodextrin.siRNA complexes) was fixed at 0.2 mg/ml.  
In order to compare the stability in serum of siRNA alone and CD complexes, siRNA 
(0.5 µg) or cyclodextrin.siRNA complexes (MR75) were incubated for different time 
intervals in 50% (v/v) fetal bovine serum (FBS) at 37 ºC [25]. Samples were then 
treated for 1 hour with excess heparin (1,000 I.U./ml) at room temperature. After 
loading onto 1.5% (w/v) agarose gels in TBE buffer containing ethidium bromide, 
electrophoresis was performed at 120 V for 30 minutes, and the resulting gels were 
photographed under UV light. 
2.3 Molecular biology, cell culture and cytotoxicity 
PC-3 cells (human prostate cancer cell line, European Collection of Cell Cultures 
(ECACC), UK) were maintained in RPMI-1640 medium (Sigma) supplemented with 
10% FBS. TRAMP C1 cells (a transgenic adenocarcinoma of the mouse prostate cell 
line, was kindly donated by Cork Cancer Research Centre (CCRC), Ireland) were 
maintained in Dulbecco’s modified Eagle’s medium high glucose with L-glutamine and 
without sodium pyruvate (Gibco, UK) supplemented with 5% FBS, 5% Nu Serum IV 
(BD Biosciences, UK), 5 µg/ml insulin from bovine pancreas, 10
-8
 mol/l 
5a-Androstan-17b-ol-3-one. All cells were grown in an incubator (ThermoForma) at 37 
ºC with 5% CO2 and 95% relative humidity.  
The pGL3-luc plasmid contains the firefly luciferase gene under the control of the 
simian vacuolating virus 40 (SV40) promoter/enhancer. The pGL3-luc plasmid was 
maintained and propagated in competent E. coli. It was isolated by alkaline lysis, 
purified by anion exchange chromatography using Plasmid Mega kit (QIAGEN) in 
accordance with the manufacturer’s instructions and stored in deionised water at 
-20 °C. Plasmid concentration was determined from the absorbance at 260 nm using 
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GeneRay UV-photometer Biometra®. Plasmid with A260/A280=1.8-2.0 was used for 
experiments. 
Cytotoxicity of β-CD, G-CD, G-CD-PEG and G-CD-PEG-AA was estimated using the 
MTT assay with 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide. 
PC-3 cells (5000 per well) were seeded in 96-well plates one day before transfection. 
The cyclodextrins were incubated with cells for 48 hours under the normal growth 
conditions. After incubation, the cyclodextrin solution was replaced with 200 µl fresh 
growth medium, and 20 µl MTT stock (5 mg/ml in PBS) was added and incubated 
with cells for 4 hours at 37 ºC. The contents were removed and 100 µl DMSO was 
added to dissolve the purple formazan products. The results were measured at 570 nm 
using a microplate reader. The concentration of CDs leading to 50% cell growth 
inhibition (IC50) was estimated from the plot of the percentage of viable cells versus 
the concentration of cyclodextrins for each treatment. 
2.4 Internalisation of cyclodextrin.fluorescein-siRNA complexes 
PC-3 cells (100,000 per well) were seeded in 12-well plates and incubated for 24 hours 
under normal growth conditions. Following incubation, cells were treated (or left 
untreated) with 40 µM haloperidol for 3 hours for the competitive binding study [31]. 
Cells were then washed with growth medium and transfected with fluorescein-siRNA 
(sense sequence 5’ – UUC UCC GAA CGU GUC ACG U – 3’, modified by 
3’-fluorescein on sense sequence, QIAGEN) (50 nM) or its cyclodextrin complex 
followed by 4-hour incubation in 10% FBS containing growth medium. After this, 
cells were treated with CellScrub™ (Genlatins) to remove uninteranlised complexes 
according to manufacturer’s instructions. The medium was then removed by aspiration, 
and cells were washed twice with pre-warmed PBS and trypsinised. After 
centrifugation (1000 rpm for 5 minutes) the supernatant was discarded and pellets 
were re-suspended in 1000 µl cold PBS in Polystyrene Round-Bottom Tubes (Becton 
Dickinson). For each sample 10,000 cells were measured out according to the Becton 
Dickinson FACScalibur manual. Fluorescein-positive cells were analysed by Dot Plot 
and by Histogram Plot (data not shown). 
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2.5 Intracellular fate of G-CD-PEG-AA.fluorescein-siRNA complexes 
TRAMP C1 cells (50,000 per well) were seeded in 12-well culture plates with glass 
bottoms (MatTek™). Anisamide-targeted formulations containing fluorescein-siRNA 
were applied to cells with a final siRNA concentration of 100 nM and incubated under 
the normal growth conditions for 30 minutes, 4 hours and 24 hours. In order to label 
late endosomes and lysosomes, 75 nM LysoTracker Red (Molecular Probes, Invitrogen) 
was added to cells for 30 minutes at 37 °C. The media was then replaced with fresh 
growth medium and observed using an Olympus FV 1000 microscope. 
Fluorescein-labeled siRNA was detected using excitation at 488 nm and emission of 
505-530 nm (green). LysoTracker Red was detected using excitation at 543 nm and an 
emission band pass filter 560 nm (red). 
2.6 In vitro reporter gene silencing by cyclodextrin.anti-luciferase siRNA complexes 
PC-3 cells were seeded at a density of 50,000 cells per well in 24-well plates. 
Following 24-hour incubation, the media was replaced with 10% FBS containing 
growth medium and transfected with 0.4 µg of pGL3-luc plasmid DNA complexed 
with FuGENE6® DNA transfection reagent (Roche). Following a 8-hour incubation, 
the media was replaced with 10% FBS containing growth medium, and luciferase GL3 
siRNAs (sense sequence 5’ – CUU ACG CUG AGU ACU UCG A – 3’, QIAGEN) 
(100 nM) formulated with G-CD-PEG or G-CD-PEG-AA (MR75) was applied to the 
cells for a further 24-hour transfection at 37 °C. Luciferase GL3 siRNA alone (100 nM) 
and negative control siRNA (sense sequence 5’ – UUC UCC GAA CGU GUC ACG U 
– 3’, no modification, QIAGEN) (100 nM) formulated with G-CD-PEG-AA were used 
as negative controls. At the endpoint of transfection, cells were washed with PBS, 
treated with 250 l of cell lysis buffer (Promega) and a freeze-thaw cycle [25]. 
Cellular debris was removed by centrifugation at 13,000 rpm for 5 minutes. The 
luciferase activity in cell lysate (20 l) was measured with 100 l of luciferin substrate 
(Promega) in a luminometer (BERTHOLD Technologies) after 10 seconds. The 
protein content was determined with Pierce BCA® Assay according to manufacturer’s 
instructions (Thermo Scientific). Luciferase gene expression was expressed as relative 
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light units (RLU) per microgram of protein.  
2.7 In vivo anti-tumour effect of cyclodextrin.VEGF siRNA complexes 
Male C57 BL/6 mice (Harlan Laboratories, UK), aged 6-8 weeks, were used. The 
animal ethics committee of University College Cork approved all experiments. The 
mice were kept at 22 ºC with a natural day/night light cycle in a conventional animal 
colony. All mice were maintained in a pathogen free animal facility for at least 2 weeks 
before the experiments. The tumour-bearing animal model was established by 
subcutaneous injection of 5 x 10
6 TRAMP C1 cells into the right flank [32]. Tumour 
growth and body weight were recorded regularly, and tumour volume was calculated 
using the formula a2b(π/6), where a is the minor diameter of the tumour and b is the 
major diameter perpendicular to diameter a. 
When tumour volume attained 100 mm³ (day 0), tumour-bearing mice (5 mice/group) 
were given intravenous injections through the tail vein on day 1, 4, 8, 11, 15 and 18, 
using mouse VEGF siRNAs (sense sequence 5’-AGG UUU CAA UAU ACA UUU 
ATT-3’, SIGMA) at a dose of 0.5 mg/kg body weight formulated in G-CD-PEG and 
G-CD-PEG-AA in a 0.1 ml injection volume. PBS, VEGF siRNA alone and 
G-CD-PEG-AA alone were used as negative controls. The mice were sacrificed on day 
22, and blood samples were collected for monitoring of Alanine aminotranferease 
(ALAT) and aspartate aminotransferase (ASAT) levels, the analysis was performed  
by the Institut Clinique de la Souris (ICS, France).  
Determination of VEGF mRNA expression was as follows. Tumor homogenates 
(obtained using a MagNA Lyser Instrument, Roche) were centrifuged at 15,000 rpm 
for 2 minutes at 4 °C to remove insoluble tissue debris and the supernatant was 
collected for reverse transcription polymerase chain reaction (RT-PCR). Total RNA 
was isolated from the supernatant using an Absolutely RNA Miniprep Kit (Stratagene), 
according instructions supplied. First-strand cDNA was generated from total RNA 
samples using High-Capacity cDNA Reverse Transcription Kits (Applied Biosystems). 
Quantitative real-time RT-PCR was performed using a Light Cycler System (Roche). 
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RT-PCR was carried out at the following thermal conditions: an initial denaturation 
step at 95 °C for 10
 
minutes, followed by 40 cycles of 15 seconds at 95 °C, annealing 
for 5
 
seconds at 55 °C, and 15 seconds
 
at 72 °C. The primers used were: mouse 18S 
ribosomal RNA (rRNA) (forward 5’-gcaattattccccatgaacg-3’ and reverse 
5’-gggacttaatcaacgcaagc-3’, Eurofins), and mouse VEGF-a (forward 
5’-gcagcttgagttaaacgaacg-3’ and reverse 5’-ggttcccgaaaccctgag-3’, Eurofins). The 
quantitative level of each VEGF mRNA was measured as a fluorescent
 
signal corrected 
according to the signal for 18S rRNA.  
2.8 Statistical analysis 
An unpaired Student’s t-test (two-tailed) was used to test the significance of 
differences between two mean values. One-way ANOVA was used to test the 
significance of differences in three or more groups. Two-way ANOVA with repeated 
measures was used to test the significance of differences in measured tumour growth 
and body weight. In all cases, p<0.05 was considered statistically significant. 
 
3. Results and discussion 
3.1 Synthesis of modified cyclodextrins 
Beta CD was modified, as described above, on the primary side with a cationic group, 
guanidino (5), which is reported to enhance cell penetration [3,6] (Figure 1a). This 
cationic CD (G-CD), in addition to the potential to enhance cellular uptake, is designed 
to complex the siRNA. A click chemistry approach, previously described by us [13], 
was used to modify the CD on the secondary side with a PEG chain to produce 
G-CD-PEG (11a).  The PEG chain is designed to mask any residual charge, to reduce 
toxicity and to enhance stability. In addition, the PEG chain was used as a spacer to 
attach the targeting ligand anisamide (11b) resulting in the synthesis of a targeted 
PEGylated CD, G-CD-PEG-AA (Figure 1b). To our knowledge there is no previous 
example of a CD-based vector which incorporates these three distinct design features, 
a cationic group (guanadino) in tandem with a PEG chain linked to a targeting moiety 
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(anisamide), all covalently attached in one CD compound.  
3.2 Formation of cyclodextrin.siRNA complexes 
The formation of cyclodextrin and siRNA complexes by interaction between positively 
charged guanidino groups of the cyclodextrins and negatively charged siRNA was 
examined by gel retardation (Figure 2a). Complete condensation of siRNA with G-CD 
took place from mass ratio MR5 onwards (data not shown), yet in the case of the 
PEGylated derivatives complete complexation of siRNA occurred only from MR50 
(G-CD-PEG) (data not shown) and MR75 (G-CD-PEG-AA) onwards, probably due to 
steric interference from the PEG-AA groups.  
Using dynamic light scattering (DLS) at MR75 (Figure 2c and d), the diameters of the 
PEGylated CDs, G-CD-PEG and G-CD-PEG-AA, and their complexes with siRNA 
after 4-hour incubation in PBS were in the range of ~210-260 nm, a similar size for the 
G-CD-PEG-AA was observed by TEM (Figure 2b). In contrast the particle sizes of  
the non-PEGylated CDs, G-CD and G-CD.siRNA complex, were significantly greater 
in the presence of PBS (Figure 2c). Zeta potentials of the PEGylated CDs (~ 14-18 
mV) were much lower than that of the guanidino cyclodextrin (~ 63 mV), and their 
surface charges were further reduced to nearly neutral (~ 7-11 mV) by condensation of 
siRNA (Figure 2d). 
To examine the ability of the cyclodextrins to protect siRNA from serum nucleases, the 
G-CD-PEG-AA.siRNA complex (MR75) was incubated in 50% FBS at 37 ºC for 24 
and 48 hours. Naked siRNA was completely degraded after 24-hour incubation, in 
contrast, up to 48 hours only slight degradation of siRNA was noted on formulation 
with G-CD-PEG-AA (Figure 2e). 
The in vivo stability of siRNA-vector particles depends on the vector structure, as well 
as on the surface charge. Although positively charged vectors can bind and protect 
siRNA against serum nuclease they tend to be toxic in vivo as they may adsorb to 
serum albumin and other anionic proteins resulting in clot-like accumulations in the 
blood [3]. These are either entrapped in the lung endothelial capillary bed or taken up 
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by the reticuloendothelial system [33]. PEGylation has been widely reported as an 
effective method to mask the surface charge, forming so called ‘stealth’ particles [6]. 
In addition, the PEG can be used as a linker to attach a targeting ligand to enhance cell 
specific uptake and compensate for the negative effects of PEG on cellular 
internalisation [6]. In this work a PEGylated CD has been synthesised and this 
molecule was further modified to attach, via the PEG chain, anisamide as a targeting 
ligand. Physicochemical charasterisation of the PEGylated CD particles, in contrast to 
the cationic nonPEGylated control, indicates the ability of the PEG to efficiently shield 
the surface charge of complexes and avoid aggregation in saline solutions. Such 
properties are a prerequisite for prospective extended blood circulation. In addition, 
the G-CD-PEG-AA.siRNA construct protected against serum nucleases and produced 
particle sizes capable of exploiting enhanced permeation and retention via the leaky 
vasculature in tumours [33].  
3.3 Cytotoxicity of cyclodextrins 
It has been reported that significantly higher cytotoxicity is caused by polycationic 
complexes compared with PEGylated complexes. In this study, the cytotoxicity of 
cyclodextrins was studied in prostate cancer cell lines using an MTT assay (Figure 3a). 
In the PC-3 cell line (a human prostate cancer cell line), G-CD, G-CD-PEG and 
G-CD-PEG-AA displayed IC50 values of 65, 850 and 790 µg/ml respectively (Figure 
3a). In the TRAMP C1 cells (a mouse prostate carcinoma cell line), G-CD, G-CD-PEG 
and G-CD-PEG-AA IC50 values were 45, 1050 and 890 µg/ml (data not shown). The 
data confirmed that PEGylated cyclodextrins are considerably less toxic, although the 
anisamide moiety slightly increased toxicity. Due to higher cytotoxicity, the 
non-PEGylated CD was not used in the following in vitro and in vivo investigations. In 
the case of the PEGylated CDs the concentrations used for subsequent in vitro studies 
ensured cell viability of > 90%.  
3.4 Internalisation, intracellular trafficking and in vitro reporter gene silencing with     
cyclodextrin.fluorescein-siRNA complexes 
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The sigma receptor is overexpressed on many human malignancies including prostate 
cancer [18]. It has been demonstrated that anisamide-conjugated lipidic nanoparticles 
achieved successfull site-specific delivery of siRNAs to such cancers [19-21]. Here, 
fluorescein-siRNA was used to examine the internalisation of anisamide-conjugated 
cyclodextrin.siRNA in PC-3 cells which overexpress sigma receptors [34]). Uptake of 
siRNA formulated with G-CD-PEG was similar to that observed for siRNA on its own 
(Figure 3b), whereas formulation with the anisamide-targeted cyclodextrin resulted in 
65-70% fluorescein-positive cells. Cellular uptake was significantly (P<0.05) reduced 
by pre-treatment with haloperidol, a known sigma antagonist [31] (Figure 3b). The 
cellular uptake of the G-CD-PEG-AA complex in TRAMP C1 cells (also overexpress 
with sigma receptors [35]) was similar to that observed in PC3 cells (data not shown). 
In addition, we have also demonstrated that G-CD-PEG-AA did not achieve cellular 
internalisation in CT26 cells (a sigma-receptor-negative cell line [19]) (data not 
shown). These results indicate that the targeted G-CD-PEG-AA.siRNA construct has 
an increased affinity for prostate cancer cells and that cellular uptake is mediated via 
the sigma receptor. 
The intracellular trafficking of the G-CD-PEG-AA.siRNA complex was studied in the 
mouse TRAMP C1 cells using fluorescently labelled siRNA (Figure 3c). After 30 
minutes incubation, no fluorescence signal was detected inside the cytoplasm. At 4 
hours, the fluorescein-siRNA was detected inside the cells, mainly in the 
endolysosomes, where the yellow colour observed is consistent with co-localisation 
with the endosomal/lysomomal marker, LysoTracker Red (Figure 3c). However, after 
24 hours, the green fluorescence became evenly dispersed and more pronounced than 
the red fluorescence, implying release of siRNA from the endolysosomes [36]. In 
contrast, other amphiphilic cationic cyclodextrins used by us, with lipid chains at the 
6-positions and amino groups on the oligo(ethylene oxide) chains at the 2-positions, 
have shown cell entry within 30 minutes after incubation [10], suggesting that 
endocytosis is highly influenced by the surface characteristics of nanoparticles. In 
addition, the intracellular trafficking of the G-CD-PEG-AA complex in PC-3 cells was 
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similar to that observed in TRAMP C1 cells (data not shown). 
The ability of G-CD-PEG-AA to deliver siRNA was further confirmed using luciferase 
GL3 siRNA to silence pGL3-luc plasmid expression in PC-3 cells. Luciferase siRNA 
formulated with anisamide-targeted cyclodextrin induced significant gene inactivation 
compared to naked luciferase GL3 siRNA and siRNA formulated with G-CD-PEG 
(Figure 3d). Relative to the scrambled siRNA formulation the siRNA formulated with 
the targeted G-PEG-CD-AA caused approximately 80% gene knockdown, indicating 
that the effect is due to RNA interference. The in vitro luciferase gene silencing of the 
anisamide-conjugated complex in TRAMP C1 cells was similar to that recorded in PC-3 
cells (data not shown). 
3.5 Anti-tumour effect following intravenous administration of 
cyclodextrin.anti-VEGF siRNA complexes 
The effect of in vivo administration of anti-VEGF siRNA formulated with PEGylated 
cyclodextrins was assessed by intravenous injections through the tail vein of TRAMP 
C1 tumour-bearing mice (n = 5 mice/group). Tumour growth (Figure 4a) showed that 
neither naked VEGF siRNA, G-CD-PEG-AA alone, nor VEGF siRNA formulated 
with G-CD-PEG, had a significant effect on tumour growth compared to the negative 
control (PBS). In contrast, G-CD-PEG-AA.VEGF siRNA achieved a significant 
(P<0.05) inhibitory effect relative to the vehicle alone and approximately a 3-fold 
reduction in tumour volume relative to PBS. RT-PCR was used to measure the 
expression of VEGF mRNA in tumour samples. The targeted G-CD-PEG-AA complex 
significantly improved VEGF knockdown compared to any of the other groups (i.e. ~ 
3.5-fold and ~ 5.5-fold reductions in VEGF mRNA relative to G-CD-PEG complex 
and G-CD-PEG-AA alone, respectively) (Figure 4b). This data indicates that the 
improved down-regulation of VEGF expression is due to site-specific delivery of 
siRNA by G-CD-PEG-AA. In addition, monitoring of mouse body weight 
demonstrated no significant loss compared to PBS controls over the treatment period 
(Figure 4c), indicating the absence of formulation-induced toxicity. 
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Alanine aminotranferease (ALAT) and aspartate aminotransferase (ASAT) are 
enzymes in liver cells that leak into general circulation when the cells are injured. 
Following treatment with the G-CD-PEG-AA.siRNA complex no significant increase 
in ALAT or ASAT was observed (Figures 4d and 4e) this taken together with the 
unaltered body weight (Figure 4c), indicates further the absence of any critical toxicity 
at the dose used. 
 
4 Conclusions 
A click chemistry approach was used to attach a PEG chain to a cationic CD. This 
PEGylated chain masked the cationic charge, and in addition, facilitated the 
attachment of the targeting group anisamide. The resulting siRNA.CD construct 
produced a near neutral particle with acceptable size. The in vitro studies with the 
anisamide targeted vector show cell specific uptake on competition with haloperidol 
indicating the integrity of the targeting ligand. Following intravenous administration a 
reduction in tumour growth was reflected in a corresponding decrease in target mRNA 
levels. Preliminary toxicity indicators, body weight and liver enzymes, indicated that 
the treatment was well tolerated. These results indicate that the anisamide conjugated 
cyclodextrin vector has potential for siRNA delivery for prostate cancer therapy. 
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Figure captions 
Figure 1. (a) Synthesis of the cationic cyclodextrin, G-CD (5) (i), PPh3, Br2, DMF; (ii), 
tert-Butyl-N-(2-mercaptoethyl)-carbamate, NaH, DMF, 60 °C; (iii), propargyl bromide, NaH, 
DMF, r.t. (iv), TFA, CH2Cl2; (v), (a) 1,3-Di-Boc-2-(trifluoromethylsulfonyl)guanidine, 
triethylamine, DCM r.t.;  b) TFA, CH2Cl2, r.t. (b) Synthesis of the PEGylated CD, G-CD-PEG 
(11a), and, the anisamide targeted CD, G-CD-PEG-AA (11b) (i), TBDMSCl, pyridine; (ii), 
propargyl bromide, NaH, DMF; (iii), PPh3, Br2, CH2Cl2, (iv), -methoxy-O-methoxy-PEG500 
-yl- azide (For 9a) or 1-deoxy- -(p-methoxybenzamido)-PEG440-yl azide (For 9b) , CuSO4.5 
H2O, sodium ascorbate, DMF-H2O, 80 °C; (v) a) tert-Butyl-N-(2-mercaptoethyl)- carbamate, 
NaH, 80 °C; b) TFA, CH2Cl2 (vi), a) N,N′-diBoc-1H-pyrazole-1-carboxamidine, DCM, 
DIPEA, r.t.; b) TFA, CH2Cl2, r.t. 
Figure 2. Physicochemical evaluation of the cyclodextrin.siRNA complexes. (a) Complexation 
of siRNA (0.5 g) with G-CD, G-CD-PEG, and G-CD-PEG-AA at different mass ratios (MRs), 
(b) Morphology of G-CD-PEG-AA.siRNA complex (scale bar = 500 nm) (MR75), (c) Particle 
sizes of CDs and CD.siRNA complexes (MR75), (d) Zeta potentials of CDs and CD.siRNA 
complexes (MR75) (* P<0.05 compared to unformulated CDs), (e) Stability of naked siRNA 
(0.5 g) and siRNA complexed with G-CD-PEG-AA (MR75) after incubation for 24- and 
48-hour in fetal bovine serum at 37 °C. 
Figure 3. In vitro investigations of cyclodextrins and cyclodextrin.siRNA complexes in 
prostate cancer cell lines. (a) Viability (MTT) of PC-3 cells treated with CDs (mean ± SD, n = 
3), (b) Fluorescein-positive PC-3 cells (%, mean ± SD) after 
G-CD-PEG-AA.fluorescein-siRNA (MR75, 50 nM siRNA) transfection with or without 
3-hour pretreatment with 40 µM haloperidol (* P<0.05 compared to the pretreatment control), 
(c) Intracellular distribution of G-CD-PEG-AA.fluorescein-siRNA (MR75, 100 nM siRNA) in 
TRAMP C1 cells at time intervals of 30 minute, 4 hour and 24 hour post-transfection using 
confocal microscopy. The images, left to right represented fluorescein, LysoTracker Red, 
merged images of fluorescein and LysoTracker Red, and transmission light. (d) Luciferase 
reporter gene silencing in PC-3 cells by naked anti-luciferase siRNA, anti-luciferase siRNA 
formulated with and without anisamide, formulated scrambled siRNA. (NS = no significance, 
* P<0.05 compared to formulated scrambled siRNA) (mean ± SD, n = 3). 
Figure 4. Influence of anti-tumour therapy following intravenous administration of 
G-CD-PEG-AA.VEGF siRNA complex (MR75) (siRNA dose = 0.5 mg/kg mouse body 
weight) in the TRAMP C1 mouse tumour model. (a) Tumour growth (mean±SD, n = 5 
mice/group) evaluated by tumour volume (NS = no significance, * P<0.05 compared to 
G-CD-PEG-AA on its own), (b) Tumour VEGF mRNA knockdown (mean±SD, n = 5 
mice/group) (NS = no significance, * P<0.05 compared to negative controls), (c) Body weight 
concurrent with tumour treatments (mean±SD, n = 5 mice/group), and Liver enzyme levels; (d) 
Alanine aminotranferease (ALAT), and, (e) aspartate aminotransferase (ASAT) (mean±SD, n = 
5 mice/group).  
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